Merchan’s Takeaways From the CLEAR Study in Advanced RCC
Jaime Merchan, MD, discusses what the potential clinical implications or takeaways for colleagues are based on findings from the phase 3 CLEAR study in advanced renal cell carcinoma (RCC).
Jaime Merchan, MD, professor, co-leader of the Translational and Clinical Oncology Research Program and director of the phase 1 clinical trials program at the Sylvester Comprehensive Cancer Center at the University of Miami, discusses what the potential clinical implications or takeaways for colleagues are based on findings from the phase 3 CLEAR study (NCT02811861) in advanced renal cell carcinoma (RCC).
The study is evaluating the treatment of lenvatinib (Lenvima) with pembrolizumab (Keytruda) for treatment of advanced RCC. A biomarker analysis of the CLEAR trial compared 3 treatments for advanced RCC: lenvatinib plus pembrolizumab, lenvatinib plus everolimus, and sunitinib (Sutent).
Findings showed that compared with sunitinib, the lenvatinib and pembrolizumab combination showed superior efficacy in this patient population, regardless of the tested markers, including gene expression signatures related to cell growth, blood vessel formation, and immune response. Specifically, significantly longer rates of progression-free survival (PFS) and overall survival (OS) were observed with lenvatinib plus pembrolizumab.
Transcription:
0:09 | The takeaway from this study is that the combination of lenvatinib and pembrolizumab is an excellent combination that is associated with high response rates, including a good number of complete responses and high median progression-free survival compared with sunitinib. This confirms the value, importance, and relevance of this combination in advanced renal cell carcinoma, regardless of any genomic transcriptomics or biomarker characteristics.
0:46 | There will be further analysis. In my opinion, there needs to be a new type of analysis that may be independent of the classical current gene signatures that are validated in renal cell carcinoma. Hopefully, in the near future, an analysis using different levels of gene expression or different signatures in RCC will be conducted.
REFERENCE:
Motzer RJ, Porta C, Eto M, et al. Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. J Clin Oncol. 2024;42(suppl 16):4504. doi:10.1200/JCO.2024.42.16_suppl.4504
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
TMLI Trial Shows Potential in Relapsed/Refractory Leukemia
October 2nd 2024In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow and lymphoid irradiation with cyclophosphamide and etoposide in high-risk acute leukemia.
Read More
